Shares of Blueprint Medicines rose Thursday after the biotech cancer drug developer’s initial public offering raised $146.6 million, above its expectations. The stock rose as much as 33 percent during the day but returned most of those gains as the market slumped.
Blueprint Medicines climbs after IPO tops estimates at $147M
by Research Team | May 2, 2015 | Health News | 0 comments